Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer  

作　　者：Sheng-Jie Sun Jin-Di Han Wei Liu Zhi-Yong Wu Xiao Zhao Xiang Yan Shun-Chang Jiao Jian Fang 

机构地区：[1]Department of Medical Oncology,The Fifth Medical Center of General Hospital of Chinese People's Liberation Army,Beijing 100039,China [2]Department of Internal Oncology of Chest,Beijing Cancer Hospital,Beijing 100142,China [3]Peking Cancer Hospital Palliative Care Center,Beijing Cancer Hospital,Beijing 100142,China [4]Department of Oncology,The Fifth Medical Center of General Hospital of Chinese People's Liberation Army,Beijing 100039,China

出　　处：《World Journal of Clinical Cases》2022年第18期6069-6081,共13页世界临床病例杂志

摘　　要：BACKGROUND Icotinib could have potential effect and tolerability when used sequentially with chemotherapy for advanced epidermal growth factor receptor(EGFR)-mutated non-small cell lung cancer(NSCLC).AIM To evaluate the efficacy and safety of chemotherapy followed by icotinib maintenance therapy as first-line treatment for advanced EGFR-mutated NSCLC.METHODS This multicenter,open-label,pilot randomized controlled trial enrolled 68 EGFRmutated stage IIIB/IV NSCLC patients randomized 2:3 to the icotinib alone and chemotherapy+icotinib groups.RESULTS The median progression-free survival in the icotinib alone and chemotherapy+icotinib groups was 8.0 mo(95%CI:3.84-11.63)and 13.4 mo(95%CI:10.18-16.33),respectively(P=0.0249).No significant differences were found in the curative effect when considering different cycles of chemotherapy or chemotherapy regimen(all P>0.05).CONCLUSION A sequential combination of chemotherapy and EGFR-tyrosine kinase inhibitor is feasible for stage IV EGFR-mutated NSCLC patients.

关 键 词：Advanced stage CHEMOTHERAPY Epidermal growth factor receptor mutation First-line treatment ICOTINIB 

分 类 号：R734.2[医药卫生—肿瘤]